Form 8K Geron Corporation For: 6 August
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Geron Corporation (GERN)
The Geron share price today is 1.5200, view NASDAQ GERN stock exchange data. Track the latest Geron share price with real-time updates on GERN stock performance including market cap, day range, 52-week range and dividend yield. Access GERN charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.5000
1.5700
52 wk Range
1.0400
2.0100
GERN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.50001.5700
52 wk Range
1.04002.0100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GERN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
4.2500
Upside
+179.61%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Form 4 Geron Corporation For: 1 July- Investing.com
- Form 8K Geron Corporation For: 6 August
- Investing.com
_800x533_L_1412520412.jpg)
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.2500
(+179.61% Upside)
Geron Corporation SWOT Analysis
Rytelo's Rise | Explore Geron's flagship product Rytelo, driving sales growth and exceeding market expectations, positioning the company as a rising star in hematologic malignancies |
Leadership Shift | New CEO appointment signals potential strategic changes, aiming to capitalize on Rytelo's success and diversify Geron's product pipeline |
Market Expansion | Delve into Geron's growth prospects, including European Union approval for Rytelo and potential new indications, with analysts projecting significant revenue growth |
Analyst Outlook | Average price target of $4.00, with "Overweight" ratings reflecting optimism despite challenges. EPS projections show improvement trend from -0.09 to -0.00 |
Geron Corporation Earnings Call Summary for Q2/2026
- Geron Q2 2026 revenue hit $57.48M, beating estimates by 4.11%; EPS loss of 2 cents missed forecast by 1 cent amid ongoing unprofitability.
- RYTELO drug sales rose 17% YoY and 11% sequentially, driving revenue growth; company expects FY2026 revenue at mid-to-high end of $220M-$240M range.
- Operating expenses fell 4% in H1 2026 despite 24% revenue growth, demonstrating improved cost discipline as commercialization strategy gains traction.
- Shares slipped 0.11% to $1.3385 in premarket trading; company holds $327M in cash and securities with current ratio of 6.78 indicating strong liquidity.
- Management plans to announce European commercialization strategy by year-end; phase 3 myelofibrosis trial continues on long-term timeline with no changes.
Last Updated: 05-08-2026, 06:16 pm
Read Full TranscriptEarnings
Latest Release
05-08-2026
EPS / Forecast
-0.02 / -0.01
Revenue / Forecast
57.48M / 55.21M
Compare GERN to Peers and Sector
Metrics to compare | GERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGERNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.4x | −10.6x | −0.4x | |
PEG Ratio | −0.61 | 0.24 | 0.00 | |
Price/Book | 4.5x | 4.4x | 2.6x | |
Price / LTM Sales | 4.8x | 75.4x | 3.1x | |
Upside (Analyst Target) | 163.2% | 50.1% | 48.6% | |
Fair Value Upside | Unlock | −3.0% | 5.8% | Unlock |
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Geron (GERN) Share Price Today?
The Geron share price today is 1.5200.
What is the current Geron (GERN) share price and day range?
As of 24-08-2026, the Geron share price is 1.5200, with a previous close of 1.5500. The share price has ranged from 1.5000 to 1.5700 today, while the 52-week range spans from 1.0400 to 2.0100.
What Is the Geron Market Cap?
As of today, Geron market cap is 976.5600M.
What Is the Geron (GERN) Share Price Target?
The average 12-month share price target for Geron is 4.2500, with a high estimate of 6 and a low estimate of 3. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +179.61% Upside potential.
What Is Geron's Earnings Per Share (TTM)?
The Geron EPS (TTM) is -0.1011.
When Is the Next Geron Earnings Date?
Geron will release its next earnings report on 11-11-2026.
From a Technical Analysis Perspective, Is GERN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Geron Trade On?
Geron is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Geron?
The stock symbol for Geron is "GERN."
How Many Times Has Geron Stock Split?
Geron has split 0 times.
How Many Employees Does Geron Have?
Geron has 258 employees.
What Is the GERN Premarket Price?
GERN's last pre-market stock price is 1.5600. The pre-market share volume is 8,700.0000, and the stock has changed by 0.0100, or 0.6500%.
What Is the GERN After Hours Price?
GERN's last after hours stock price is 1.5300, the stock has changed by 0.0100, or 0.6600%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.